Adagio Therapeutics annonce de nouvelles données in vitro mettant en évidence une activité neutralisante large et puissante de l’ADG20 contre tous les variants connus du SARS-CoV-2

Les données seront présentées lors de la conférence virtuelle ISIRV-OMS 2021

WALTHAM, Massachusetts, 19 oct. 2021 (GLOBE NEWSWIRE) — Adagio Therapeutics, Inc. (Nasdaq : ADGI), une société biopharmaceutique au stade clinique axée sur la découverte, le développement et la commercialisation de solutions à base d’anticorps pour les maladies infectieuses à potentiel pandémique, a annoncé aujourd’hui de nouvelles données in vitro démontrant l’activité neutralisante conservée de son anticorps monoclonal (mAb), ADG20, contre un panel diversifié de variants du SARS-CoV-2 en circulation, y compris les variants Lambda et Mu récemment apparus. Les résultats montrent notamment que l’ADG20 exerce une puissante activité neutralisante in vitro contre tous les variants du SARS-CoV-2 préoccupants testés, y compris ceux présentant une sensibilité réduite aux produits mAb actuellement disponibles dans le cadre d’une autorisation d’utilisation en urgence (EUA, Emergency Use Authorization) ou à un stade avancé de développement. Ces données seront présentées au cours d’une séance de présentation d’affiches lors de la conférence virtuelle ISIRV-OMS 2021, qui se tiendra du 19 au 21 octobre 2021. En outre, Adagio présentera une nouvelle affiche mettant en évidence les données récemment annoncées de l’essai de phase 1 de l’entreprise portant sur l’ADG20 chez des participants en bonne santé.

« Ces nouvelles données sur les variants mettent en évidence l’efficacité potentielle de l’ADG20 contre la pandémie de COVID-19 en cours, ainsi que contre d’éventuelles épidémies futures causées par d’autres virus similaires au SARS », a déclaré Laura Walker, co-fondatrice et directrice scientifique d’Adagio. « Nous avons délibérément conçu ce mAb pour qu’il ait une activité neutralisante large et puissante, ainsi qu’une demi-vie qui étend sa fenêtre de protection potentielle — des caractéristiques essentielles qui pourraient le distinguer des autres thérapies disponibles dans le cadre d’une EUA ou en cours de développement aujourd’hui. Avec les essais mondiaux de prévention et de traitement de phase 2/3 en cours, nous sommes impatients de poursuivre notre évaluation de l’ADG20 afin d’évaluer le rôle significatif qu’il pourrait jouer dans l’arsenal des options de traitement contre la COVID-19. Administré sous forme d’injection intramusculaire unique dans les essais cliniques, l’ADG20 a été conçu pour offrir une protection allant jusqu’à un an dans le cadre de la prévention et on étudie actuellement sa possible efficacité dans le traitement des patients à haut risque et/ou en tant que complément de vaccin, y compris pour les personnes immunodéprimées. »

En plus de l’essai de phase 1 sur des participants sains, Adagio fait progresser deux essais mondiaux de phase 2/3 en cours avec l’ADG20, un essai de traitement (STAMP) et un essai de prévention (EVADE). La société prévoit de soumettre une demande d’EUA à la Food and Drug Administration des États-Unis pour l’ADG20 au cours du premier trimestre 2022.

Détails de la présentation
Titre de l’affiche : (130) Broad and Potent In Vitro Neutralization of SARS-CoV-2 Variants by ADG20, a Half-Life Extended Monoclonal Antibody in Development for the Prevention and Treatment of COVID-19 (Neutralisation large et puissante in vitro des variants du SARS-CoV-2 par l’ADG20, un anticorps monoclonal à demi-vie prolongée en cours de développement pour la prévention et le traitement du COVID-19)

Titre de l’affiche  :(131) Evaluating the Safety, Tolerability, and Pharmacokinetics of ADG20, a Half-Life–Extended Monoclonal Antibody (mAb) in Development for the Prevention and Treatment of COVID-19: a Preliminary Analysis of a Randomized Phase 1 Study (Évaluation de l’innocuité, de la tolérabilité et de la pharmacocinétique de l’ADG20, un anticorps monoclonal (mAb) à demi-vie prolongée en cours de développement pour la prévention et le traitement de la COVID-19 : une analyse préliminaire d’une étude randomisée de phase 1)

À propos de l’ADG20
L’ADG20, un anticorps monoclonal ciblant la protéine spike du SARS-CoV-2 et des coronavirus connexes, est en cours de développement aux fins de la prévention et du traitement de la COVID-19, la maladie provoquée par le SARS-CoV-2. L’ADG20 a été conçu et élaboré en vue d’offrir de puissantes et vastes capacités de neutralisation du SARS-CoV-2 et des autres sarbecovirus du clade 1 permettant de cibler un épitope bien conservé dans le domaine de fixation du récepteur. L’ADG20 exerce une puissante activité neutralisante in vivo contre la souche originale du SARS-CoV-2 et tous ses variants préoccupants connus. L’ADG20 pourrait avoir un impact sur la réplication virale et la maladie subséquente grâce à de multiples mécanismes d’action, notamment le blocage direct de l’entrée virale dans la cellule hôte (neutralisation) et l’élimination des cellules hôtes infectées par l’activité effectrice immunitaire innée médiée par Fc. L’ADG20 est administré par une seule injection intramusculaire et a été conçu pour avoir une longue demi-vie, dans le but de fournir une protection à la fois rapide et durable. Adagio fait progresser l’ADG20 grâce à de multiples essais cliniques à l’échelle mondiale.

À propos d’Adagio Therapeutics
Adagio (Nasdaq : ADGI) est une société biopharmaceutique au stade clinique axée sur la découverte, le développement et la commercialisation de solutions à base d’anticorps pour les maladies infectieuses présentant un potentiel pandémique. Le portefeuille d’anticorps de la société a été optimisé grâce aux capacités de pointe d’Adimab en matière d’ingénierie d’anticorps et est conçu pour fournir aux patients et aux cliniciens une combinaison inégalée de puissance, d’ampleur, de protection durable (grâce à l’extension de la demi-vie), de faisabilité de fabrication et de prix abordable. Le portefeuille d’anticorps anti-SARS-CoV-2 d’Adagio comprend plusieurs anticorps fortement neutralisants non concurrents dotés d’épitopes de liaison distincts, dirigés par l’ADG20. Adagio a conclu avec des sous-traitants tiers un contrat portant sur des capacités de fabrication pour la production de l’ADG20 afin de soutenir l’achèvement des essais cliniques et le lancement commercial initial, garantissant ainsi une large accessibilité aux populations du monde entier. Pour plus d’informations, rendez-vous sur notre site www.adagiotx.com.

Énoncés prospectifs
Le présent communiqué de presse contient des énoncés prospectifs au sens de la loi Private Securities Litigation Reform (Réforme sur la résolution des litiges portant sur des titres privés) de 1995. Des mots tels que « anticipe », « croit », « s’attend à », « l’intention », « des projets » et « à l’avenir » ou des expressions similaires sont destinés à identifier des énoncés prospectifs. Les énoncés prospectifs comprennent des énoncés concernant, entre autres, le calendrier, les progrès et les résultats de nos études précliniques et essais cliniques sur l’ADG20, y compris le calendrier de notre demande d’EUA prévue, le lancement et l’achèvement d’études ou d’essais et de travaux préparatoires connexes, la période durant laquelle les résultats des essais seront disponibles et nos programmes de recherche et développement ; notre capacité à obtenir et conserver des approbations réglementaires pour nos produits candidats ; notre capacité à identifier les patients atteints des maladies traitées par nos produits candidats et à recruter ces patients dans nos essais cliniques ; nos capacités et notre stratégie de fabrication ; et notre capacité à commercialiser avec succès nos produits candidats. Nous pourrions ne pas réellement atteindre les plans, intentions ou attentes divulgués dans nos énoncés prospectifs et vous ne devez pas vous fier indûment à nos énoncés prospectifs. Ces énoncés prospectifs impliquent des risques et des incertitudes qui pourraient faire en sorte que nos résultats réels diffèrent sensiblement des résultats décrits ou sous-entendus par les énoncés prospectifs, y compris, sans s’y limiter, les risques décrits sous la rubrique « Risk Factors » (Facteurs de risque) dans le rapport trimestriel d’Adagio sur le formulaire 10-Q pour le trimestre clos le 30 juin 2021 et dans les futurs rapports qu’Adagio déposera auprès de la SEC. De tels risques peuvent être amplifiés par les impacts de la pandémie de COVID-19. Les énoncés prospectifs contenus dans le présent communiqué de presse sont formulés à cette date, et Adagio décline toute obligation de mettre à jour ces informations sauf si la loi en vigueur l’exige.

Contacts :

Contact auprès des médias :
Dan Budwick, 1AB
Dan@1abmedia.com

Contact auprès des investisseurs :
Monique Allaire, THRUST Strategic Communications
monique@thrustsc.com

Bill & Melinda Gates Foundation Commits up to $120 Million to Accelerate Access to COVID-19 Drug for Lower-Income Countries, Calls on Other Donors to Mobilize Resources

Financial commitment aims to secure dedicated, low-cost supply of molnupiravir, if the drug is authorized by regulators; builds on long-term efforts to increase access to tests, treatments, vaccines

SEATTLE, Oct. 20, 2021 /PRNewswire/ — The Bill & Melinda Gates Foundation announced today a commitment of up to $120 million to accelerate access to the investigational antiviral drug molnupiravir for lower-income countries as part of its COVID-19 response effort. The funding will be allocated based on consultations with partners, and will support the range of activities required to develop and manufacture generic versions of the drug, which is being developed by Merck & Co in collaboration with Ridgeback Biotherapeutics.

This commitment builds on the foundation’s ongoing efforts, including $1.9 billion in funding, since the start of the pandemic to increase access to COVID-19 vaccines, treatments, and tests by supporting R&D, regulatory work, at-risk manufacturing, and product delivery.

“To end this pandemic, we need to ensure that everyone, no matter where they live in the world, has access to life-saving health products. The unjust reality, however, is that low-income countries have had to wait for everything from personal protective equipment to vaccines. That is unacceptable,” said Melinda French Gates, co-chair of the Gates Foundation. “Today’s commitment will ensure that more people in more countries get access to the promising drug molnupiravir, but it’s not the end of the story—we need other donors, including foundations and governments, to act.”

Initial data reported by Merck suggest that molnupiravir, a broad-spectrum antiviral, can cut the risk of serious disease and death due to COVID-19 by half. Molnupiravir would be the first oral outpatient drug authorized for use in treating COVID-19 patients with mild and moderate disease—a critical breakthrough to prevent hospitalizations and save lives in combination with increased vaccination coverage and existing treatments for severely and critically ill patients. The decision on whether to authorize the drug for use sits with regulatory agencies, including the World Health Organization (WHO) and national governments.

“Africa CDC and the Africa Union have been tracking the exciting developments on the antiviral, molnupiravir,” said John Nkengasong, director of the Africa Centers for Disease Control and Prevention. “In order to make sure that Africa is not left behind, we have been working with the Bill & Melinda Gates Foundation colleagues on various mechanisms they can facilitate, once all of the regulatory processes are completed and the drug is officially made available to the world.”

This commitment leverages the resources of the foundation’s Strategic Investment Fund, which uses a suite of financial tools—including loans and volume guarantees—to address market failures and incentivize private enterprises to develop affordable and accessible health products. The foundation’s previous work to lower costs and increase access to life-saving drugs includes dolutegravir, an HIV drug. In 2017, the foundation established a volume guarantee with two generic suppliers that has brought therapies containing the drug to more than 18 million people in lower-income countries, in coordination with the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) and the Global Fund to Fight AIDS, Tuberculosis and Malaria.

Strive Masiyiwa, African Union special envoy on COVID-19 response, said, “We applaud the foundation for its commitment and look forward to continuing our collaboration to ensure this potentially lifesaving treatment, upon regulatory approval, is accessible to as many Africans as possible. This would be a step forward in balancing the inequities seen to date in availability of innovations during the pandemic.”

The foundation has already provided expertise and funding to help strengthen generics manufacturers, including $1.3 million to Medicines for All Institute (M4ALL) and the University of Manchester to develop low-cost manufacturing processes that dramatically reduce the cost of raw materials and increase product yields. Several generics manufacturers are investigating these improvements already as they plan to scale up production following regulatory authorization. The foundation has also provided $2.4 million in grants to expedite generic company readiness to apply for WHO prequalification and start manufacturing when prequalification is granted.

“Merck has taken important steps to make this drug available as a COVID-19 therapy, including negotiating licenses with generics manufacturers to increase supply. We are pleased to work alongside these efforts to ensure affordability and availability in lower-income countries,” said Bill Gates, co-chair of the Gates Foundation. “Making life-saving drugs like these available to everyone who needs them is what is necessary to end the acute phase of the pandemic, and open pathways to recovery.”

The goal is to significantly reduce the time it takes for a new drug to reach low-income countries after it becomes available in high-income markets. The standard gap in rolling out global health products can be 12 months or more.

“We have a unique set of resources and expertise that we dedicate to ensuring that everyone, everywhere has access to life-saving health interventions,” said Mark Suzman, chief executive officer of the Gates Foundation. “This is what the foundation does best. We will work with companies, procurement agencies, and donors to make molnupiravir available to low-income countries. Our funding is part of what’s needed to ensure equitable supply. We call on other donors and partners to help mobilize the multiples of additional resources required.”

Since the start of the pandemic, the foundation has worked closely with a range of partners on R&D and delivery of COVID-19 tools. These partners include philanthropic and government donors that are part of the COVID-19 Therapeutics Accelerator and global organizations in the therapeutics pillar of the access to COVID-19 Tools Accelerator (ACT-A) partnership, including Unitaid, UNICEF, WHO, the Global Fund, Wellcome, and the Africa Medical Supplies Platform. The foundation will continue to work with multilateral organizations, nongovernmental organizations, governments, and other partners to ensure that clinical, regulatory, and delivery pathways are ready once molnupiravir and its generic versions become available.

About the Bill & Melinda Gates Foundation
Guided by the belief that every life has equal value, the Bill & Melinda Gates Foundation works to help all people lead healthy, productive lives. In developing countries, it focuses on improving people’s health and giving them the chance to lift themselves out of hunger and extreme poverty. In the United States, it seeks to ensure that all people—especially those with the fewest resources—have access to the opportunities they need to succeed in school and life. Based in Seattle, Washington, the foundation is led by CEO Mark Suzman, under the direction of Bill Gates and Melinda French Gates.

Media contact: media@gatesfoundation.org

UN says Catastrophic Flooding Causes Devastation in South Sudan

GENEVA —

The U.N. refugee agency reports weeks of unrelenting rain and heavy flooding in South Sudan have washed away whole communities and wiped out the livelihoods of hundreds of thousands of people.

Floods are not new to South Sudan. What is new is the frequency and intensity of the flooding. UNHCR representative in South Sudan, Arafat Jamal, describes the current flooding, which has affected more than 700,000 people, as being of near biblical proportions.

“People have lived with flooding for millennia, but they have been able to cope. They have been able to move to higher ground when the floods are there, and then come down when they recede. But when you have a high-level flooding year after year, that destroys the crops and does not allow you to replant. That is when you have got an erosion (in) peoples’ ability to survive,” Jamal expressed.

He points out the present floods have hit at a time when people in South Sudan are facing the triple threat of conflict, COVID-19, and hunger. He says the devastating flooding is expected to continue as the climate crisis intensifies.

He notes Jonglei, Unity, Northern Bahr el Ghazal and Upper Nile are the worst affected states. “I have seen people stranded on islands. I have heard from people who have had to survive by eating grass and roots. And we have also heard of people who have had to walk for 10 days to access dry land. It is also hugely destructive in terms of assets. This is an agricultural country and a country that depends upon its herds of cattle,” Jamal says.

Cattle have also been affected. They are stranded and drowning, mired in the mud and unable to survive. And whole fields of sorghum, mangoes, and millet are destroyed by flooding, he says.

He says the UNHCR together with South Sudan’s government are delivering urgently needed aid to the most vulnerable. That aid includes hygiene items, food, emergency shelter and solar lanterns to provide light.

However, he adds much more assistance is needed and is appealing to the international community to help rebuild the affected communities and restore people’s lives and livelihoods.

Source: Voice of America

State Department Recap: October 13-20

WASHINGTON —

Here’s a look at what U.S. Secretary of State Antony Blinken and other top diplomats have been doing this week:

US-South America

Promoting democracy and managing migration are the focus of Blinken’s first trip to Ecuador and Colombia from October 19 to 21 as top U.S. diplomat. During a speech Wednesday in Quito, Blinken outlined challenges facing democracies in the Western Hemisphere but said he was optimistic they could be overcome.

Venezuela also looms large as the U.S. calls for political talks to resume between the Venezuelan government and the country’s opposition. U.S. officials this week discussed ways to tackle irregular migration, as Colombia hosts nearly 2 million Venezuelan migrants, and Ecuador also hosts a large number of migrants from Venezuela.

China also came up during Blinken’s South American trip. Ecuadorian officials described Beijing as “a commercial partner,” with Ecuadorian President Guillermo Lasso saying he wanted to secure a trade deal with China. Blinken told his Ecuadorian counterpart the U.S. was not asking countries to choose between Washington and Beijing, but he warned of risks of doing business with Chinese companies, saying “there really is no division between purportedly private enterprises and the state.”

US ‘One China’ Policy

Nicholas Burns, President Joe Biden’s nominee to be the next U.S. ambassador to China, took a tough line on dealings with China during his Senate confirmation hearing Wednesday. Burns said the U.S. was right to continue its “one-China policy” but that Washington was also right to oppose China’s unilateral actions that undermine the status quo and undermine the stability of the region. Noticeably, Burns used the wordings of Washington’s so-called one-China “policy,” which is different from Beijing’s one-China “principle.” The U.S. has “acknowledged” but has never endorsed the Chinese Communist Party’s claim of sovereignty over Taiwan.

Colin Powell’s legacy

Colin Powell, the first Black U.S. secretary of state and a top military officer, died Monday at age 84 from complications due to COVID-19 while battling multiple myeloma.

He is being remembered by America’s foreign service work force, who say Powell was devoted to ensuring the State Department was properly resourced, consulted and respected.

Powell, who shaped lasting U.S. policies toward Africa, also is being remembered on the continent for peacemaking, supporting the fight against AIDS and sounding the alarm against war abuses.

US-Haiti

Haitian protesters took to the streets this week to demand the release of 17 missionaries — 16 Americans and 1 Canadian — kidnapped on October 16 by the 400 Mawozo gang. An interagency team dispatched by the U.S. government is working closely with Haitian authorities to try to recover the missionaries. The State Department has raised its travel advisory for Haiti to Level 4: Do Not Travel.

Top US envoy to afghanistan steps down

The U.S. special envoy to Afghanistan, Zalmay Khalilzad, stepped down from his post this week, less than two months after the chaotic U.S. withdrawal from Afghanistan. Blinken announced Khalilzad’s departure in a statement Monday, saying the envoy would be replaced by his deputy, Thomas West. Talk of Khalilzad’s resignation had emerged since August after the Afghan Security Forces collapsed and the Taliban rapidly took control over the war-torn country.

Tigray violence

The U.S. remains gravely concerned by escalating violence in Tigray.

Forces in Ethiopia’s Tigray region said Monday that the Ethiopian government had launched airstrikes on the regional capital, Mekelle. The United States also was looking into the reported attack, with State Department spokesperson Ned Price saying the U.S. remained “gravely concerned by what has been escalating violence in Tigray for some time.”

China missile test

Top U.S. officials said Washington was paying close attention to China’s efforts to build up its military arsenal, amid reports Beijing took a major step forward two months ago by testing a hypersonic missile. Monday, the State Department said the U.S. was “deeply concerned” about the rapid expansion of China’s nuclear capabilities, which is deviating from Beijing’s decades-long nuclear strategy based on minimum deterrence.

Iran nuclear deal

Efforts to get Tehran to return to the terms of the Iran nuclear deal are in danger of falling short, forcing the United States and its allies to consider nondiplomatic options to contain the threat, according to top U.S. officials.

Jerusalem consulate

The United States will move ahead with its plan to reopen the U.S. consulate in Jerusalem as Washington restores ties with the Palestinians and commits to a two-state solution. “As I said in May, we’ll be moving forward with the process of opening a consulate as part of deepening those ties with the Palestinians,” Blinken said during a Wednesday press conference. But he stopped short of providing a timeline.

Source: Voice of America

US Charges Leaders of Neo Black Movement of Africa in Internet Scam

The U.S. Secret Service said in a statement Wednesday that an investigation it conducted with the FBI has led to federal charges related to internet scams against seven leaders of the Cape Town Zone of the Neo Black Movement of Africa, also known as “Black Axe.”

An eighth man, who allegedly conspired with the leader of the group, was also charged with federal crimes linked to internet scams stemming from South Africa, the Secret Service said.

The Secret Service statement said the following people were charged wire fraud, money laundering and other crimes in connection with perpetrating romance scams and other illegal schemes perpetrated on victims in the U.S. and other countries between 2011 and 2021 using the internet:

• Perry Osagiede, 52, aka “Lord Sutan Abubakar de 1st,” aka “Rob Nicolella,” aka “Alan Salomon.”

• Enorense Izevbigie, 45, aka “Richy Izevbigie,” aka “Lord Samuel S Nujoma.”

• Franklyn Edosa Osagiede, 37, aka “Lord Nelson Rolihlahla Mandela,” aka “Edosa Franklyn Osagiede,” aka “Dave Hewitt,” aka “Bruce Dupont.”

• Osariemen Eric Clement, 35, aka “Lord Adekunle Ajasi,” aka “Aiden Wilson.”

• Egbe Tony Iyamu, 35, aka “Lord Aminu Kano,” aka “Richard Amall.”

• Collins Owhofasa Otughwor, 37, aka “Lord Jesse Makoko,” aka “Philip Coughlan.”

• Musa Mudashiru, 33, aka “Lord Oba Akenzua.”

All originally from Nigeria, the suspects are charged by superseding indictment with wire fraud conspiracy and money laundering conspiracy spanning from 2011 to 2021. Perry Osagiede, Franklyn Osagiede, Clement, Izevbigie, and Iyamu are also charged with wire fraud. Perry Osagiede, Franklyn Osagiede, Iyamu and Otughwor are charged with aggravated identity theft.

Toritseju Gabriel Otubu, 41, also known as “Andy Richards” and “Ann Petersen” and also originally from Nigeria, was charged in a separate indictment with wire fraud conspiracy and wire fraud, aggravated identity theft, and money laundering conspiracy, spanning from 2016 to 2021.”

Acting U.S. Attorney Rachael Honig said in the statement that “Americans are too often victimized by criminal organizations located abroad that use the internet to deceive those victims, defraud them of money, and, many times, persuade their victims to wittingly or unwittingly assist in perpetuating the fraudulent schemes.”

“The public should be on guard against schemes like these,” she added. “And, more importantly, anyone thinking of engaging in this kind of criminal conduct should understand that the U.S. Attorney’s Office and our partners will find them and bring them to justice, no matter where they are.”

The statement said: “The wire fraud conspiracy and wire fraud charges each carry a maximum term of 20 years in prison and a maximum fine of $250,000. The money laundering conspiracy charge carries a maximum term of 20 years in prison and a maximum fine of $500,000 or twice the value of the property involved in the transaction, whichever is greatest. The aggravated identity theft charges carry a mandatory term of two years in prison, which must run consecutively to any other term of imprisonment imposed on a defendant.”

Source: Voice of America

Botswana Allays Concerns Over Rhino Poaching Crisis

GABORONE —

Botswana wildlife authorities have refuted reports the country’s rhinoceros population is on the verge of extinction due to poaching. The southern African country has battled a rise in poaching, with more than 60 animals killed in the last two years.

Department of Wildlife and National Parks Director Kabelo Senyatso said both rhinoceros and elephant poaching remain under control.

In a statement addressing poaching concerns, Senyatso said the government is committed to protecting the key species.

He added that, while isolated reports of poaching both the rhino and elephant continue to be reported, the government’s anti-poaching efforts are making progress.

But conservationist Neil Fitt said poaching incidents could have dropped due to the decrease in the number of rhinoceroses in the Okavango Delta.

“Rhino poaching could have subsided only because there is lot less numbers there,” Fitt said. “Elephant poaching is still happening, but we are getting very little reports because the government is not saying what is happening.”

In a bid to stem the poaching tide, government security forces have killed more than 20 poachers in the last two years as part of a zero-tolerance campaign that Botswana has enforced since 2013.

Fitt said a multi-stakeholder approach to fighting poaching is key.

“The best that we can do is we all work together – the government, the private sector and NGOs. Sometimes you need to put your hand up and say we have got a problem, we need to solve it, and we need everyone to help, and we are open to all ideas, not just ideas that we like,” he said.

Map Ives, former director at Rhino Conservation Botswana, said there is a need for an intelligence-based approach to counter poaching.

“That intelligence comes in several layers,” Ives said. “You need local intelligence within the Okavango Delta. You need local plus intelligence, which is surrounding the Okavango Delta, and then you need regional intelligence that is from countries surrounding Botswana, including Namibia, Angola, Zambia and Zimbabwe. And then you need international intelligence. This sort of intelligence requires a high level of trust, not only government but between the private sector and NGOs.”

According to a 2021 International Rhino Foundation status report released last month, the rhino population faces a significant poaching threat in Botswana.

But, the report notes, the government is taking steps to address the issue, including dehorning the rhinos to make them less attractive to poachers and relocating the animals to safer places.

Source: Voice of America